Professor Jonathan Williams, one of the UK’s leading organic chemists, has received a Royal Society Wolfson Merit Award for his research.
Williams, from the University of Bath’s Department of Chemistry, is the recipient of a £10,000 a year award over a five-year period. The award will fund his research group’s work in designing metal catalysts for new chemical reactions.
In many cases, the metal catalysts developed by the group allow reactions to be more environmentally friendly because molecules can be constructed more efficiently and use less energy.
Professor Paul Raithby, Head of the Department of Chemistry, said: ‘Jonathan is undoubtedly one of the most creative and productive organic chemists of his generation in the UK. His work has influenced academic chemistry internationally, as well as having had significant impact in industrial practice.
‘Jonathan has attracted a talented group of organic chemists to Bath and we are determined to support him in further developing the department’s international reputation as a leading centre for catalysis and chemical synthesis. This award is a significant contribution to that goal.’
Until recently, the research group worked on a method of constructing chemical bonds using catalytic reactions that they termed ‘Borrowing Hydrogen Methodology’. This focused on the metal catalyst temporarily removing hydrogen from the starting material, allowing it to react more easily.
Williams said: ‘The resulting compounds from this technique are made more cleanly than they would be traditionally. Using our methodology, the only by-product created is water, and there is no need to use carcinogenic starting materials.’
The group has since changed its focus and the Wolfson Merit Award will fund research into new catalytic reactions.
‘We’re now focusing on developing new approaches to the formation of amides, the chemical bonds found in proteins, in many drug molecules, and in robust materials such as Nylon and Kevlar,’ said Williams.
‘This new research will aim to identify catalytic methods for the formation of amides, which are traditionally prepared using cumbersome, inefficient chemistry.’
Bath professor receives Wolfson Merit Award
The award will fund Jonathan Williams\' research into metal catalysts for new chemical reactions
You may also like
Drug Delivery
Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody
The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Research & Development
FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design
The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline
Research & Development
Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive
Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage
Research & Development
Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic
Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform
Research & Development
Early stage clinical trials highlight the convergence of novel therapeutics and enabling technologies
Early stage clinical development is increasingly being shaped by advances in drug discovery and the technologies and manufacturing strategies that enable the safe, precise and scalable delivery of new therapies
Research & Development
Breast cancer is the world’s most studied disease for fifth consecutive year according to analysis from Phesi
The US led global clinical trial activity in 2025 and across all top five indications, with China recording the fastest growth in the number of recruiting clinical trial sites
Research & Development
One in ten Britons are using or interested in using GLP-1s for weight loss, according to new research
GLP-1 use and interest was more prevalent among women, as well as those who reported difficulties with their finances or who had experienced psychological distress within the previous month